Published in Proc Natl Acad Sci U S A on March 21, 2016
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Phase Behavior of Mixed Lipid Monolayers on Perfluorocarbon Nanoemulsions and its Effect on Acoustic Contrast. RSC Adv (2016) 0.75
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Ann Oncol (2016) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
Exploiting homing abilities of cell carriers: Targeted delivery of nanoparticles for cancer therapy. Biochem Pharmacol (2017) 0.75
Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc Natl Acad Sci U S A (2017) 0.75
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res (2001) 3.48
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell (2015) 2.57
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A (2009) 1.63
Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem (1997) 1.56
Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta (2009) 1.55
Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem (2003) 1.44
Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol (2003) 1.43
Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol (1999) 1.33
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev (2015) 1.32
Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res (2004) 1.25
Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem (2009) 1.11
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs (2013) 1.02
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res (2014) 0.94
Microvessel count predicts metastasis and prognosis in patients with gastric cancer. J Surg Oncol (1997) 0.88
Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine (2014) 0.86
Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. Mol Pharmacol (1999) 0.86
Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res (2013) 0.85